Shuttle Pharmaceuticals
Shuttle Pharmaceuticals is a publicly traded micro-cap company operating an AI-driven drug discovery platform (Molecule.ai) and a Dogecoin mining subsidiary (United Dogecoin), targeting pharmaceutical researchers and digital asset accumulation through serial acquisitions and equity financings.
- Company typePublic
- Founded2013
- HeadquartersRockville, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Shuttle Pharmaceuticals does
Shuttle Pharmaceuticals Holdings, Inc. is a publicly traded micro-cap pharmaceutical and digital infrastructure company headquartered in Gaithersburg, Maryland, listed on NASDAQ under ticker SHPH. Originally founded in 2012-2013 as a cancer treatment and radiation therapy development company, Shuttle has pivoted its business model through two recent acquisitions: the November 2025 acquisition of Canadian AI company Molecule.ai for $8 million, and the May 2026 acquisition of Dogecoin mining company United Dogecoin Inc., supported by approximately $11 million in PIPE financing. The company now operates a dual business model spanning AI-driven drug discovery and cryptocurrency mining.
The Molecule.ai platform, the company's core technology asset, is an AI-driven pharmaceutical software platform for molecular discovery and early-stage drug development. It combines machine learning, generative AI, and predictive analytics with structured scientific workflows, offering capabilities including molecule property prediction, gene-disease pathway analysis, compound interaction prediction, multimodal data processing, and a recently launched next-generation autonomous AI agent system for multi-step reasoning and multi-agent orchestration. The platform targets pharmaceutical companies, biotech firms, and research institutions via direct enterprise sales, though no commercial customers or pricing are disclosed. The United Dogecoin subsidiary is deploying up to 3,000 ElphaPex DG1+ mining rigs at an expected hash rate of approximately 43,200 GH/s, representing roughly 1.5% of global Dogecoin mining capacity, powered by hydroelectric energy secured at $0.064 per kWh, with a strategy of mining and holding DOGE as a treasury asset.
The company's GTM motion relies heavily on capital markets activity, including serial public offerings, private placements, and PIPE financings totaling more than $30 million across 2023-2026, intermediated by WestPark Capital and E.F. Hutton & Co. Management includes interim co-CEO Christopher Cooper (via consulting agreement with Number 2 Capital Corp.), co-CEO Ryan Trasolini (founder of United Dogecoin), and CFO Yuying Liang. The company has undergone a 10-for-1 reverse stock split in June 2026 to comply with Nasdaq listing requirements, reflecting stress signals including a market capitalization of approximately $5.76 million and trading near 52-week lows. No revenue is disclosed and the company exhibits characteristics of an early-stage platform pursuing a turnaround through inorganic expansion.
Shuttle Pharmaceuticals firmographics
Firmographics- Name
- Shuttle Pharmaceuticals
- Legal name
- Shuttle Pharmaceuticals Holdings, Inc.
- Website
- https://shuttlepharma.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Shuttle Pharmaceuticals is a publicly traded micro-cap company operating an AI-driven drug discovery platform (Molecule.ai) and a Dogecoin mining subsidiary (United Dogecoin), targeting pharmaceutical researchers and digital asset accumulation through serial acquisitions and equity financings.
- Ownership category
- akta.pro rank
Shuttle Pharmaceuticals industry classification
Industry- Product category
- AI-driven Pharmaceutical Drug Discovery Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro industry
- AI/ML Platforms for Drug Discovery & Experiment OptimizationHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
Keywords
Where Shuttle Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Shuttle Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- AI Drug Discovery Platform (Molecule.ai): The company licenses or provides access to its Molecule.ai AI-driven platform for pharmaceutical molecular discovery and drug development, serving biotech and pharmaceutical researchers. Revenue is generated through platform licensing, subscriptions, or usage-based fees for drug discovery services.
- Dogecoin Mining (United Dogecoin): Through its wholly-owned subsidiary United Dogecoin Inc., Shuttle Pharmaceuticals operates Dogecoin mining using ElphaPex DG1+ mining hardware. Revenue is generated from mined DOGE cryptocurrency, which the company intends to hold on its balance sheet as a treasury strategy. Energy costs are secured at competitive rates (hydroelectric at $0.064/kWh).
- Capital Markets / Equity Financing: Shuttle Pharmaceuticals raises capital through public offerings of common stock and pre-funded warrants, private placements, and PIPE financings to fund acquisitions, marketing, working capital, and corporate purposes.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Shuttle Pharmaceuticals product offering
Product offeringCore offering
Shuttle Pharmaceuticals develops and commercializes AI-driven pharmaceutical software for molecular discovery and early-stage drug development through its Molecule.ai platform, with capabilities spanning computational drug design and automated chemistry synthesis. The company also operates cryptocurrency mining through its United Dogecoin Inc. subsidiary and continues legacy work on radiation sensitizer candidates for cancer radiotherapy.
Product overview
Shuttle Pharmaceuticals operates a dual business model consisting of (1) Molecule.ai, an AI-driven pharmaceutical software platform for molecular discovery and early-stage drug development that helps researchers explore chemical space, evaluate molecular ideas, and identify gene-disease pathway relationships; and (2) United Dogecoin, a wholly-owned subsidiary operating in the cryptocurrency mining sector as a Dogecoin mining company. The company transitioned from its original focus on cancer treatment and radiation therapy development to AI-powered drug discovery and digital asset mining.
Differentiator
Problem solved
Functional benefit
Brands
- Molecule.ai: AI-driven platform for molecular discovery and early-stage drug development that helps researchers explore chemical space efficiently and evaluate molecular ideas with greater clarity.
Products and services
- Molecule.ai AI-driven pharmaceutical software platform for molecular discovery, computational drug design, automated chemistry synthesis, and early-stage drug development, serving pharmaceutical, biotechnology, and research customers.
- RSP-100 Radiation Sensitizer Series (including RSP-150) Radiation sensitizer drug candidates developed to improve tumor response to radiation therapy in oncology treatment settings, targeted at clinical investigators and oncology research programs.
- United Dogecoin Cryptocurrency Mining Operations Cryptocurrency mining operations operated through the United Dogecoin Inc. subsidiary, providing digital asset mining capacity as an additional revenue vertical for the company.
- ShuttleDx AI-driven pharmaceutical software offering for molecular discovery and drug development applications, complementing the Molecule.ai platform within Shuttle Pharmaceuticals' software portfolio.
Quantifiable outcome
- Potential to materially reduce drug development timelines, lower costs, and increase probability of success across the development pipeline
Companies that use Shuttle Pharmaceuticals
Customer profileSegments2 records
Ideal customer profiles2 records
Shuttle Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature6 records
Shuttle Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- United Dogecoin Inc.coreShuttle Pharmaceuticals acquired United Dogecoin Inc. through a definitive merger agreement with a concurrent $11 million PIPE financing. United Dogecoin is a Dogecoin mining company that became a wholly-owned subsidiary of Shuttle. The combined entity aims to become the largest publicly listed Dogecoin mining company by global hashrate percentage, with a strategy of mining Dogecoin and holding mined DOGE on its balance sheet. E.F. Hutton & Co. served as exclusive M&A advisor and placement agent.
- Theradex SystemsminorShuttle Pharmaceuticals settled liabilities with Theradex Systems for $300,000 as part of its ongoing corporate and financial obligations.
- Doctronic / Utah Office of Artificial Intelligence PolicyminorUtah launched a pilot program through the state's Office of Artificial Intelligence Policy powered by Doctronic for AI-based prescription refills without physician involvement. Shuttle Pharma positioned this initiative as validation of the broader shift toward AI automation in healthcare, relevant to the company's AI-driven drug discovery and radiotherapy capabilities.
- Molecule.aicoreShuttle Pharmaceuticals completed the acquisition of Canadian AI company Molecule.ai for $8 million (including cash, stock, and contingent payments based on milestones). Molecule.ai's platform utilizes advanced machine learning models to accelerate therapeutic development. The acquisition aims to enhance Shuttle's technological capabilities in drug development and precision radiotherapy solutions, expanding the company's AI-driven pharmaceutical software portfolio.
Scale indicators11 records
Recent moves6 records
Expansion highlights5 records
Shuttle Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Hut 8: Publicly traded digital asset mining and infrastructure company with diversified energy and hosting operations. Comparable to United Dogecoin's mining-plus-data-center strategy.
Emerging players
- Insilico Medicine: AI-driven drug discovery platform with end-to-end capabilities from target identification through clinical-stage molecules. Comparable to the predictive and generative AI workflow claims of Molecule.ai.
- Valo Health: AI-enabled drug discovery platform combining patient data, genomics, and ML to identify therapeutic candidates. Comparable in its use of multimodal data and predictive modeling for early-stage discovery.
- Atomwise: AI-driven small-molecule drug discovery company using structure-based deep learning models. Comparable to Molecule.ai's molecular property prediction and compound interaction prediction features.
Direct peers
- Exscientia: AI-native pharma company using generative AI and automation for small-molecule drug design and discovery. Closely aligned with Molecule.ai's molecule property prediction and compound interaction capabilities.
- Riot Platforms: Publicly traded crypto mining company with a focus on low-cost energy infrastructure, similar to United Dogecoin's hydroelectric energy strategy. Comparable in operational model and capital markets exposure.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining machine learning with high-throughput biology to accelerate early-stage pharma R&D. Comparable to Molecule.ai's stated mission of using AI to compress early-stage drug development timelines.
- Schrödinger: Publicly traded AI-driven molecular simulation and drug discovery software platform serving pharma and biotech researchers. Most direct publicly listed comparable to Molecule.ai, with a similar licensing/subscription model for computational chemistry and predictive analytics.
- Marathon Digital Holdings: Largest publicly traded cryptocurrency mining company (Bitcoin). Comparable to United Dogecoin as a publicly listed, capital-markets-driven crypto mining operation, though focused on Bitcoin rather than Dogecoin.
Regional players
- CleanSpark: Publicly traded Bitcoin mining company with a focus on low-cost, sustainable energy and energy-efficient infrastructure. Comparable to United Dogecoin's strategy of securing low-cost hydroelectric power for crypto mining.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Shuttle Pharmaceuticals social profiles
Digital presenceShuttle Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Shuttle Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles6 records
Shuttle Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries2 records
Shuttle Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds8 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Shuttle Pharmaceuticals M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Shuttle Pharmaceuticals
What does Shuttle Pharmaceuticals do?
Shuttle Pharmaceuticals develops and commercializes AI-driven pharmaceutical software for molecular discovery and early-stage drug development through its Molecule.ai platform, with capabilities spanning computational drug design and automated chemistry synthesis. The company also operates cryptocurrency mining through its United Dogecoin Inc. subsidiary and continues legacy work on radiation sensitizer candidates for cancer radiotherapy.
Is Shuttle Pharmaceuticals a public or private company?
Shuttle Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Shuttle Pharmaceuticals founded?
Shuttle Pharmaceuticals was founded in 2013. It employs 1 to 10 people.
Where is Shuttle Pharmaceuticals based?
Shuttle Pharmaceuticals is headquartered in Rockville, United States, in the North America region.
How does Shuttle Pharmaceuticals make money?
Three revenue lines are on record. AI Drug Discovery Platform (Molecule.ai) is the primary driver. The others are dogecoin Mining (United Dogecoin) and capital Markets / Equity Financing.
Who are Shuttle Pharmaceuticals's main competitors?
Hut 8 is listed as a broad incumbent. Emerging players are Insilico Medicine, Valo Health and Atomwise. Direct peers are Exscientia, Riot Platforms, Recursion Pharmaceuticals, Schrödinger and Marathon Digital Holdings. CleanSpark is listed as a regional player.
Does Shuttle Pharmaceuticals have an API?
No public API is recorded for Shuttle Pharmaceuticals.
What industry is Shuttle Pharmaceuticals in?
Shuttle Pharmaceuticals's product category is AI-driven Pharmaceutical Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.